RTOG 0625\/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS).<\/p>
Of 123 enrolled patients, 107 had baseline and at least 1 posttreatment MRI. Two central neuroradiologists serially measured bidimensional (2D) and volumetric (3D) enhancement on postcontrast T1-weighted images and volume of FLAIR hyperintensity. Progression status on all posttreatment MRIs was determined using Macdonald and RANO imaging threshold criteria, with a third neuroradiologist adjudicating discrepancies of both progression occurrence and timing. For each MRI pulse sequence, Kaplan-Meier survival estimates and log-rank test were used to compare OS between cases with or without radiologic progression.<\/p>
Two sets of XLS spreadsheets (ACRIN-DSC-MR-Brain TCIA Anonymized and ACRIN-DSC-MR-Brain-HB TCIA Anonymized) are needed in order to obtain the entire clinical data set for this collection. The file sets are a random sample of ACRIN 6677 participants divided into 2 groups. Group 1\/ACRIN-DSC-MR-Brain TCIA Anonymized: a 75% random sample; Group 2\/ACRIN-DSC-MR-Brain-HB TCIA Anonymized: a 25% random sample initially held for testing\/validating algorithms trained on the 75% sample.\u00a0 Both are available via the clinical download button.<\/span><\/p> Radiologic progression occurred after 2 chemotherapy cycles (8 weeks) in 9 of 97 (9%), 9 of 73 (12%), and 11 of 98 (11%) 2D-T1, 3D-T1, and FLAIR cases, respectively, and 34 of 80 (43%), 21 of 58 (36%), and 37 of 79 (47%) corresponding cases after 4 cycles (16 weeks). Median OS among patients progressing at 8 or 16 weeks was significantly less than that among nonprogressors, as determined on 2D-T1 (114 vs 278 days and 214 vs 426 days, respectively; P < .0001 for both) and 3D-T1 (117 vs 306 days [P < .0001] and 223 vs 448 days [P = .0003], respectively) but not on FLAIR (201 vs 276 days [P = .38] and 303 vs 321 days [P = .13], respectively).<\/p> Early progression on 2D-T1 and 3D-T1, but not FLAIR MRI, after 8 and 16 weeks of anti-vascular endothelial growth factor therapy has highly significant prognostic value for OS in recurrent GBM.<\/p> This shared data set was provided in collaboration with the American College of Radiology Core Lab. Many thanks are due to the ACRIN 6667 trial team, and all the patients participating in the study.\u00a0\u00a0<\/span>This study was supported by the\u00a0American College of Radiology Imaging network (ACRIN),<\/span>\u00a0which received funding from the National Cancer Institute through\u00a0UO1 CA080098, U01\u00a0CA190254<\/span>\u00a0and\u00a0R50\u00a0CA211270 (Muzi)<\/span>, under the American Recovery and Reinvestment ACT of 2009 (ARRA) and UO1 CA079778.<\/span><\/p>RESULTS:<\/h4>
CONCLUSION:<\/h4>
Acknowledgements<\/strong><\/h3>